Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine containing microorganisms and hypoglycemic and lipid-lowering medicine

A hypoglycemic and lipid-lowering, microbial technology, applied in medical preparations, drug combinations, pharmaceutical formulas and other directions containing active ingredients, can solve the problems of weight loss drugs failing to achieve the expected effect, adverse reactions of patients, etc., to enhance the weight loss effect, avoid Resistance and related side effects, the effect of reducing fasting blood sugar

Pending Publication Date: 2021-08-10
MOON (GUANGZHOU) BIOTECH CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But many weight loss drugs don't work as expected, or because they cause serious adverse effects in patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine containing microorganisms and hypoglycemic and lipid-lowering medicine
  • Combined medicine containing microorganisms and hypoglycemic and lipid-lowering medicine
  • Combined medicine containing microorganisms and hypoglycemic and lipid-lowering medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] In this example, the use of MNO-863 strains and / or Liraglutide (liraglutide) drugs was tested in vivo in a high-fat diet-induced obesity mouse model to verify its effectiveness in the treatment or prevention of obesity, diabetes and liver disease. use.

[0091] (1) Experimental animals: 50 C57BL / 6J male mice (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) were purchased, all of which were fed normally and aged 5 weeks. The mice were kept in the same environment during the growth process. Eight of them were fed with SPF-grade rat maintenance feed (purchased from Guangzhou Hancheng Experimental Equipment Co., Ltd.), and 42 were fed with D12492 high-fat feed (purchased from Parker Bio) for about 8 to 10 weeks. Afterwards, weighing, the diet-induced obesity model modeling standard is that the body weight reaches 38.00±2.00g.

[0092] (2) The strain to be tested: MNO-863 cultured in anaerobic mode, the culture medium is 104 liquid culture medium (the formula ...

Embodiment 2

[0115] This embodiment carries out the in vivo test of the use of Parabacteroides distasonis (Parabacteroides distasonis) strain and / or Liraglutide drug in high-fat diet-induced obesity mouse model, to verify its effect in the treatment or prevention of obesity, diabetes and liver disease use.

[0116] (1) Experimental animals: 50 C57BL / 6J male mice (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) were purchased, all of which were fed normally and aged 5 weeks. The mice were kept in the same environment during the growth process. Eight of them were fed with SPF-grade rat maintenance feed (purchased from Guangzhou Hancheng Experimental Equipment Co., Ltd.), and 42 were fed with D12492 high-fat feed (purchased from Parker Bio) for about 8 to 10 weeks. Afterwards, weighing, the diet-induced obesity model modeling standard is that the body weight reaches 38.00±2.00g.

[0117](2) Bacterial strains for testing: Parabacteroides distasonis of anaerobic culture, culture ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a combined medicine containing microorganisms and a hypoglycemic and lipid-lowering medicine, and relates to the technical field of strain separation and application. The combined medicine containing the microorganisms and the blood glucose and lipid lowering medicine can be applied to treatment or prevention of liver function impairment, liver function impairment related diseases, diabetes mellitus, obesity and obesity related diseases. The inventor verifies that the combined medicine containing the microorganisms and the hypoglycemic and lipid-lowering medicine has the technical effect of synergistic interaction, the combined medicine has the treatment effect better than that of the single application of the microorganisms or the single application of the hypoglycemic and lipid-lowering medicine, and the microorganisms can enhance the weight losing effect of the hypoglycemic and lipid-lowering medicine, improve abnormal glucose tolerance and reduce fasting blood glucose. In addition, the combined medicine has no toxic or side effect on the kidney and can reduce the weight of the liver.

Description

technical field [0001] The invention relates to the technical field of bacterial strain isolation and application, in particular to a combined drug comprising microorganisms and blood sugar and lipid-lowering drugs. This application claims the priority of the Chinese patent application with the application number 2021103702491 titled "combined drug comprising microorganisms and hypoglycemic and lipid-lowering drugs" submitted to the Chinese Patent Office on April 06, 2021, the entire contents of which are incorporated by reference in this application. Background technique [0002] At present, liver diseases are mainly prevented through strategies such as vaccination against hepatitis and reducing alcohol consumption. However, for the treatment of liver diseases, there is a lack of effective treatments or drugs with few side effects. [0003] Currently, there is no cure for diabetes, and at this stage, diabetes is mainly controlled through drug therapy. However, the efficac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61K38/22A61K35/74A61P3/06A61P3/10A61P3/04
CPCA61K35/74A61K38/22A61K38/26A61P3/06A61P3/10A61P3/04
Inventor 林诠盛蒋先芝邝祖鹏黄宝家孔萍邓茜莹赵莹莹肖晨张腾勋邝茜雯泰利宏
Owner MOON (GUANGZHOU) BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com